29
NOV
2021

Northwest Biotherapeutics Announces $15 Million Financing

Posted By :
Comments : Off
BETHESDA, Md., November 29, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company’s cash reserves above $20 million. The Company plans to use the funding to help accelerate its activities related to its brain cancer program. The...
Read More
28
OCT
2021

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

Posted By :
Comments : Off
BETHESDA, Md., October 28, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company’s manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year....
Read More
12
MAY
2021

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Posted By :
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Application Submitted to MHRA for Certification of Sawston Facility BETHESDA, Md., May 12, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing...
Read More
16
MAR
2021

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

Posted By :
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility Application for MHRA Regulatory Certification of Facility In Preparation BETHESDA, Md., March 16, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax®...
Read More
05
OCT
2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

Posted By :
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com BETHESDA, Md., October 5, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. With the database now locked, the...
Read More